Business Wire
-
Ingersoll Rand to Acquire ILC Dover to Expand Presence in Life Sciences
3/25/2024
Ingersoll Rand Inc. (NYSE:IR), a global provider of mission-critical flow creation and industrial solutions, has entered into an agreement to acquire ILC Dover (“ILC”) from New Mountain Capital, LLC, a leading growth-oriented investment firm with approximately $50 billion in assets under management. The deal includes an upfront cash purchase price of approximately $2.325 billion and an earnout tied to the achievement of select operating efficiency metrics in 2024. At its maximum payout, the earnout
-
Kite Receives U.S. FDA Approval of Manufacturing Process Change Resulting in Reduced Median Turnaround Time for Yescarta® CAR T-cell Therapy
1/30/2024
Kite, a Gilead Company (Nasdaq: GILD), today announced that the U.S. Food and Drug Administration (FDA) has approved a manufacturing process change resulting in a shorter manufacturing time for Yescarta® (axicabtagene ciloleucel). With this approval, Kite’s median turnaround time (TAT) in the U.S. is anticipated to be reduced from 16 days to 14 days. Median TAT is defined as time from leukapheresis, when a patient’s T cells are collected, to product release; manufacturing is
-
Paratek Pharmaceuticals Strengthens Senior Leadership Team
6/4/2015
Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) today announced the addition of two experienced pharmaceutical executives to the company's senior leadership team to meet the company's growing needs as it advances the development program for its lead investigational antibiotic, omadacycline, and as it expands the company's pre-commercialization capabilities.
-
DCAT Announces Sharp Sourcing 2015
6/2/2015
The Drug, Chemical & Associated Technologies Association (DCAT) announces DCAT Sharp Sourcing 2015, a conference and networking event for pharmaceutical, biopharmaceutical companies and suppliers in the pharmaceutical manufacturing value chain.
-
Bioserv Corporation And Advantar Laboratories Announce Collaboration To Create A Comprehensive Value Chain
3/18/2013
Bioserv Corporation, a leading provider of pharmaceutical cGMP contract manufacturing, clinical packaging and cold chain and distribution services, is pleased to announce that it has entered into a non-exclusive Collaboration Agreement with Advantar Laboratories Inc., a provider of high-quality, customer service driven analytical testing, biophysical characterization, drug product formulation and litigation support services to pharmaceutical and biotechnology companies.
-
BioInvent Recruits New Chief Executive Officer
1/9/2013
BioInvent International AB recently announced that Svein Mathisen has resigned from his positions as chief executive officer of the Company and as member of the Board of Directors.
-
Baxter Initiates Phase I Clinical Trial With Anti-MIF Antibody In Patients With Solid Tumors
9/5/2012
Baxter International Inc. has begun dosing patients with malignant solid tumors in a Phase I clinical trial of a monoclonal antibody, representing the company’s efforts to extend its oncology portfolio with advanced biological research and development.
-
LipoScience Receives FDA Clearance for Vantera Clinical Analyzer
9/5/2012
LipoScience, Inc., an in vitro diagnostic company, announced that it has received 510(k) clearance from the FDA to market the Vantera® Clinical Analyzer, which is the first NMR analyzer designed specifically for the clinical laboratory.
-
Edimer Receives FDA Fast Track Designation For Lead Compound EDI200
6/14/2012
Edimer Pharmaceuticals, a biotechnology company focused on developing an innovative therapy for the rare genetic disorder, X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), recently announced the receipt of Fast Track designation from the U.S. Food and Drug Administration (FDA) for EDI200, the company’s novel, proprietary, recombinant protein.
-
Bristol-Myers Squibb And Gilead Sciences Announce Licensing Agreement for Development And Commercialization Of New Fixed-Dose Combination Pill For People Living With HIV
10/27/2011
Bristol-Myers Squibb Company (NYSE: BMY) and Gilead Sciences, Inc. (Nasdaq: GILD) today announced a licensing agreement for Bristol-Myers Squibb to develop and commercialize a fixed-dose combination containing Bristol-Myers Squibb’s protease inhibitor REYATAZ®(atazanavir sulfate) and Gilead’s cobicistat, a pharmacoenhancing or "boosting" agent that increases blood levels of certain HIV medicines to potentially allow for one pill once daily dosing.